Biotechnology

BioShield shortcomings subject of industry conference

Published in Biotech Law Weekly, July 2nd, 2004

Despite the approval of $5.6 billion in federal funding for vaccines and treatments to fend off or respond to a bioterror attack, and efforts to streamline the approval process for those drugs, many companies are reluctant to enter the market, biotech industry executives and observers say.

Liability, manufacturing concerns and uncertainty about how the money will be allocated are among the reasons for the reluctance, despite the passage of the BioShield funding bill by the U.S. House and Senate. Those concerns are the subject of a conference June 9, 2004, hosted by the University of Maryland School of Law.

VaxGen President Lance K. Gordon said his...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2004-07-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry